Lorazepam (Ativan® and generic) is a benzodiazepine that is used as an anxiolytic. Here is basic information about this medication.
1. Anxiety disorders
2. Short-term relief of symptoms of anxiety
3. Anxiety associated with depressive symptoms
Note: Lorazepam (I.M/I.V.) is FDA-approved only for the treatment of status epilepticus and as a preanesthetic (for sedation, relief of anxiety, and decreased ability to recall events related to surgery).
Anxiety disorders or symptoms of anxiety
Initial: 2–3 mg/day in 2-3 divided doses
Usual: 2–6 mg/day in divided doses (largest dose at bedtime)
Daily range: 1–10 mg/day
Insomnia due to anxiety or transient situational stress
2–4 mg single dose, usually at bedtime
Initial: 1–2 mg/day in divided doses
Increased if needed and tolerated
Dosage forms and strengths
Tablets (Ativan® and generic): 0.5 mg , 1 mg (scored), 2 mg (scored)
Oral concentrate (generic): 2 mg/mL
I.M./I.V. Injection (Ativan® and generic): 2 mg/mL, 4 mg/mL
Please refer to Prescribing Information (see link below) for complete discussion of dosage, administration, warnings and precautions, contraindications, etc.
Alprazolam (Xanax® or Xanax® XR)
Three important pieces of information about benzodiazepines
Complete change in how to use hydroxyzine
Relaxation Practice: A Simple and Powerful Tool for Anxiety, Tension, and Insomnia
Lorazepam (Ativan®) Prescribing Information
Lorazepam Oral Solution Prescribing Information
Lorazepam Injection Prescribing Information
Copyright 2016, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons, or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply: